Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects

NCT02972905 | Completed Phase 1

• 1 other identifier: 205759
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3-Kinase (PI3K) delta inhibitor being developed as an anti-inflammatory and anti-infective agent for the treatment of inflammatory airway diseases, such as chronic obstructive pulmonary disease (COPD). The purpose of the study is to assess the safety, tolerability and pharmacokinetics (PK) of single and repeat doses of GSK2269557 administered via the ELLIPTA dry powder inhaler (DPI) to healthy Japanese subjects. This is the first time for Japanese subjects that GSK2269557 will be administered via the ELLIPTA DPI with the addition of magnesium stearate. In each group of this study, subjects will receive a single dose of either GSK2269557 or placebo in Session 1 and receive daily dose of GSK2269557 or placebo for 10 days in Session 2. Session 1 of the next dose strength may be run in parallel with the Session 2 of the previous dose. The doses planned for the study are 200 micrograms (mcg), 500 mcg and 700 mcg. There will be at least 10 days washout between the two dosing sessions. Follow up period will start 10 days (+-1 day) after the last dose of Session 2. A total number of 36 subjects will be enrolled for the study with 27 subjects receiving a dose strength of GSK2269557 and 9 subjects will receive each dose strength of GSK2269557. ELLIPTA is a trademark of the GSK group of companies.

Conditions

Pulmonary Disease, Chronic Obstructive

Keywords

pharmacokinetics; GSK2269557; Dry powder Inhaler (DPI); tolerability; safety; ELLIPTA

Outcome Measures

Primary Outcomes (37)

• Number of subjects with any adverse event(s) (AE) and serious adverse event(s) (SAE)

  An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment will be categorized as SAE.

  Approximately up to 37 days

• Session 1: Number of subjects having abnormal clinical laboratory parameters as a measure of safety

  Blood samples will be collected to analyse blood urea nitrogen, creatinine, glucose (fasting), uric acid, high density lipoprotein-cholesterol, amylase, potassium, sodium, calcium, triglycerides, lactate dehydrogenase (LDH), chloride, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total cholesterol, gamma-glutamyl transpeptidase (GGT), phosphorus, total bilirubin, direct bilirubin, total protein, albumin, low density lipoprotein-cholesterol, creatine phosphokinase (CPK)

  Approximately up to 4 days

• Session 2: Number of subjects having abnormal clinical laboratory parameters as a measure of safety

  Blood samples will be collected to analyse blood urea nitrogen, creatinine, glucose (fasting), uric acid, high density lipoprotein-cholesterol, amylase, potassium, sodium, calcium, triglycerides, LDH, chloride, AST, ALT, ALP, total cholesterol, GGT, phosphorus, total bilirubin, direct bilirubin, total protein, albumin, low density lipoprotein-cholesterol, CPK

  Approximately up to 22 days

• Session 1:Number of subjects having abnormal hematology laboratory parameters as a measure of safety

  Blood samples will be collected to analyse platelet count, Red Blood Cells (RBC) count, hemoglobin, hematocrit, RBC Indices, mean corpuscular volume ( MCV), mean corpuscular hemoglobin (MCH), percent reticulocytes, White Blood Cells (WBC), neutrophils, lymphocytes, monocytes, eosionophils, and basophils

  Approximately up to 4 days

• Session 2: Number of subjects having abnormal hematology laboratory parameters as a measure of safety

  Blood samples will be collected to analyse platelet count, RBC count, hemoglobin, hematocrit, RBC Indices, MCV, MCH, percent reticulocytes, WBC, neutrophils, lymphocytes, monocytes, eosionophils, and basophils

  Approximately up to 22 days

• Session 1: Number of subjects having abnormal urinalysis as a measure of safety

  Urine samples will be collected to analyse specific gravity, pH, glucose, protein, blood, ketones, bilirubin, and urobilinogen for dipstick, and microscopic examination

  Approximately up to 4 days

• Session 2: Number of subjects having abnormal urinalysis as a measure of safety

  Urine samples will be collected to analyse specific gravity, pH, glucose, protein, blood, ketones, bilirubin, and urobilinogen for dipstick, and microscopic examination

  Approximately up to 22 days

• Session 1: Body temperature assessment as a safety measure

  Temperature will be recorded in a supine position after 5 minutes rest

  Approximately up to 4 days

• Session 2: Body temperature assessment as a safety measure

  Temperature will be recorded in a supine position after 5 minutes rest

  Approximately up to 22 days

• Session 1: Blood pressure assessment as a safety measure

  Systolic and diastolic blood pressure will be measured in a supine positon after 5 minutes rest

  Approximately up to 4 days

• Session 2: Blood pressure assessment as a safety measure

  Systolic and diastolic blood pressure will be measured in a supine position after 5 minutes rest

  Approximately up to 22 days

• Session 1: Measurement of pulse rate as a safety measure

  Pulse rate will be measured in a supine position after 5 minutes rest

  Approximately up to 4 days

• Session 2: Measurement of pulse rate as a safety measure

  Pulse rate will be measured in a supine position after 5 minutes rest

  Approximately up to 22 days

• Session 1: Electrocardiogram (ECG) assessment as a measure of safety.

  Single 12-lead ECG will be obtained in a supine position after 5 minutes rest using an ECG machine that measures PR, QRS, QT, and Corrected QT interval by Fridericia's formula (QTcF) intervals. Single ECGs will be obtained at each time point.

  Approximately up to 4 days

• Session 2: ECG assessment as a measure of safety.

  Single 12-lead ECG will be obtained in a supine position after 5 minutes rest using an ECG machine that measures PR, QRS, QT, and QTcF intervals. Single ECGs will be obtained at each time point.

  Approximately up to 22 days

• Session 1: Spirometry assessment as a safety measure

  Spirometry assessments will be performed whilst the subject is in a standing position. Assessments will be repeated until 3 technically acceptable measurements have been made.

  Approximately up to 4 days

• Session 2: Spirometry assessment as a safety measure

  Spirometry assessments will be performed whilst the subject is in a standing position. Assessments will be repeated until 3 technically acceptable measurements have been made.

  Approximately up to 22 days

• Session 1: Area under the plasma concentration curve (AUC) from time zero to the time of last quantifiable concentration [AUC(0-t)]

  Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC \[0-t\]

  Pre-dose, 5, 15, 30 minutes (min), 1, 2 , 4 , 6, 12, 24, 36, 48, and 72hours (h) post-dose

• Session 1: AUC from time zero to 24 hours post dose [AUC(0-24)] of GSK2269557 following a single dose administration

  Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC\[0-24\]

  Pre-dose, 5, 15, 30 min, 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose

• Session 1: AUC from time zero to infinity [AUC(0-infinity)] of GSK2269557 following a single dose administration

  Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC (0-infinity).

  Pre-dose, 5, 15, 30 min, 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose

• Session 2: AUC from time zero to the time of last quantifiable concentration [AUC(0-t)] of GSK2269557 following repeat dose administration

  Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC \[0-t\]

  Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose

• Session 2: AUC from time zero to 24 hours post dose [AUC(0-24)] of GSK2269557 following repeat dose administration

  Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC\[0-24\]

  Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose

• Session 2: AUC from time zero to infinity [AUC(0-infinity)] of GSK2269557 following repeat dose administration

  Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC (0-infinity)

  Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose

• Session 1: Trough observed plasma drug concentration (Ctrough) of GSK2269557 following a single dose administration

  Blood samples will be collected at pre-dose and at specific post dose time points for calculating Ctrough

  Pre-dose, 5, 15, 30 minutes (min), 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose

• Session 1: Maximum observed plasma concentration (Cmax) of GSK2269557 following a single dose administration

  Blood samples will be collected at pre-dose and at specific post dose time points for calculating Cmax

  Pre-dose, 5, 15, 30 minutes (min), 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose

• Session 1: Maximum/trough observed plasma drug concentration (Cmax/Ctrough) of GSK2269557 following a single dose administration

  Blood samples will be collected at pre-dose and at specific post dose time points for calculating Cmax/Ctrough

  Pre-dose, 5, 15, 30 minutes (min), 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose

• Session 2: Trough observed plasma drug concentration (Ctrough) of GSK2269557 following repeat dose administration

  Blood samples will be collected at pre-dose and at specific post dose time points for calculating Ctrough

  Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose

• Session 2: Maximum observed plasma concentration (Cmax) of GSK2269557 following repeat dose administration

  Blood samples will be collected at pre-dose and at specific post dose time points for calculating Cmax

  Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose

• Session 2: Maximum/trough observed plasma drug concentration (Cmax/Ctrough) of GSK2269557 following repeat dose administration

  Blood samples will be collected at pre-dose and at specific post dose time points for calculating Cmax/Ctrough

  Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose

• Session 1: Time to maximum observed plasma drug concentration (Tmax) of GSK2269557 following a single dose administration

  Blood samples will be collected at pre-dose and at specific post dose time points for calculating tmax

  Pre-dose, 5, 15, 30 min, 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose

• Session 1: Terminal half-life (t1/2) of GSK2269557 following a single dose administration

  Blood samples will be collected at pre-dose and at specific post dose time points for calculating t1/2

  Pre-dose, 5, 15, 30 min, 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose

• Session 2: Time to maximum observed plasma drug concentration (Tmax) of GSK2269557 following repeat dose administration

  Blood samples will be collected at pre-dose and at specific post dose time points for calculating tmax

  Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose

• Session 2: Terminal half-life (t1/2) of GSK2269557 following repeat dose administration

  Blood samples will be collected at pre-dose and at specific post dose time points for calculating tmax and t1/2

  Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose

• Ratio of accumulation factor (Ro) of GSK2269557 following single and repeat inhalations

  Ro is defined as AUC(0-24) of Session 2 at day10 divided by AUC(0-24) of Session1

  Day 1 of session 2 and day 10 of session 2

• Ratio of accumulation factor (Rs) of GSK2269557 following single and repeat inhalations

  Rs is defined as AUC(0-24) of Session 2 at day10 divided by AUC(0-infinity) of Session 1

  Day 1 of session 2 and day 10 of session 2

• Ratio of accumulation factor (R[Cmax]) of GSK2269557 following single and repeat inhalations

  R\[Cmax\] is defined as Cmax of Session 2 at day10 divided by Cmax of Session 1

  Day 1 of session 2 and day 10 of session 2

• Ratio of accumulation factor (R[Ctrough]) of GSK2269557 following single and repeat inhalations

  R\[Ctrough\] is defined as Ctrough of Session 2 at day10 divided by C24 of Session 1

  Day 1 of session 2 and day 10 of session 2

Study Arms (8)

Session 1: Placebo

PLACEBO COMPARATOR

Subjects will receive a single dose inhalation of GSK2269557 matching placebo via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.

Drug: Placebo ELLIPTA DPI

Session 1: GSK2269557 200 mcg

EXPERIMENTAL

Subjects will receive a single dose inhalation of GSK2269557 200 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.

Drug: GSK2269557 ELLIPTA DPI

Session 1: GSK2269557 500 mcg

EXPERIMENTAL

Subjects will receive a single dose inhalation of GSK2269557 500 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.

Drug: GSK2269557 ELLIPTA DPI

Session 1: GSK2269557 700 mcg

EXPERIMENTAL

Subjects will receive a single dose inhalation of GSK2269557 700 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.

Drug: GSK2269557 ELLIPTA DPI

Session 2: Placebo

PLACEBO COMPARATOR

Subjects will receive repeated doses of GSK2269557 matching Placebo once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.

Drug: Placebo ELLIPTA DPI

Session 2: GSK2269557 200 mcg

EXPERIMENTAL

Subjects will receive repeated doses of GSK2269577 200mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.

Drug: GSK2269557 ELLIPTA DPI

Session 2: GSK2269557 500 mcg

EXPERIMENTAL

Subjects will receive repeated doses of GSK2269577 500mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.

Drug: GSK2269557 ELLIPTA DPI

Session 2: GSK2269557 700 mcg

EXPERIMENTAL

Subjects will receive repeated doses of GSK2269577 700mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.

Drug: GSK2269557 ELLIPTA DPI

Interventions

GSK2269557 ELLIPTA DPI DRUG

GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.

Session 1: GSK2269557 200 mcg; Session 1: GSK2269557 500 mcg; Session 1: GSK2269557 700 mcg; Session 2: GSK2269557 200 mcg; Session 2: GSK2269557 500 mcg; Session 2: GSK2269557 700 mcg

Placebo ELLIPTA DPI DRUG

Placebo ELLIPTA DPI contains lactose

Session 1: Placebo; Session 2: Placebo

Eligibility Criteria

• Age: 20 Years - 64 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Participant must be 20 to 64 years of age inclusive, at the time of signing the informed consent.

You may not qualify if:

• Normal spirometry (forced expiratory volume in 1 second \>=80% of predicted) at Screening.
• Body weight \>=50 kilograms (kg) and body mass index (BMI) within the range 18.5 to 24.9 kg/square meter (m\^2) (inclusive).
• Japanese Male: A male participant must agree to use contraception of this protocol during the treatment period and until follow up visit.
• Capable of giving signed informed consent as described in restrictions listed in the informed consent form (ICF).
• History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study treatment; or interfering with the interpretation of data
• Abnormal blood pressure as determined by the investigator
• ALT \>1.5x upper limit of normal (ULN)
• Bilirubin \>1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%)
• Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
• QTcF \>450 milliseconds (msec).
• Past or intended use of over-the-counter or prescription medication including herbal medications within 14 days prior to dosing.
• History of donation of blood or blood products \>=400 milliliters (mL) within 3 months or \>=200 mL within 1 month prior to screening
• Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day
• Current enrollment or past participation within the last 30 days before signing of consent in this clinical study involving an investigational study treatment or any other type of medical research
• The subject is positive Serological test for syphilis (rapid plasma reagin and Treponema pallidum), Human immunodeficiency virus (HIV) Antigen/Antibody, Hepatitis B surface antigen (HbsAg), Hepatitis C virus (HCV) antibody, or Human T-cell lymphotropic virus type 1 (HTLV-1) antibody at screening.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Fukuoka, 813-0017, Japan

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 14, 2016
• First Posted: November 25, 2016
• Study Start: October 1, 2016
• Primary Completion: December 1, 2016
• Study Completion: December 1, 2016
• Last Updated: January 18, 2017

Record last verified: 2017-01

Locations

JP (1)